Universal Influenza A Vaccine in Healthy Adults
Completed · Phase 1 · NCT05155319
Conditions: Human Influenza
At a glance
- Research payments reported, 2025
- $62,738
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Emergent BioSolutions
- Tested
- UFluA 20 µg each antigen/dose (biological), UFluA 60 µg each antigen/dose (biological), Placebo (biological)
- Dates
- Started 2021-12-01; completion 2023-10-10
- Results posted
- Not yet
The goal of this Phase 1, single- center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability and immunogenicity of UFluA vaccine candidate at two dose levels and two schedules in healthy adult (18-45-year-old, inclusive) male and non-pregnant female subjects.
From ClinicalTrials.gov, last updated 2025-01-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Emergent Biosolutions Inc. reported $62,738 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $62,738
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.